Free Trial

Aclarion (ACON) Competitors

$0.30
+0.01 (+3.45%)
(As of 06/14/2024 ET)

ACON vs. NVTA, MDXH, FRES, OPGN, CNTG, LH, DGX, NTRA, EXAS, and RDNT

Should you be buying Aclarion stock or one of its competitors? The main competitors of Aclarion include Invitae (NVTA), MDxHealth (MDXH), Fresh2 Group (FRES), OpGen (OPGN), Centogene (CNTG), Laboratory Co. of America (LH), Quest Diagnostics (DGX), Natera (NTRA), Exact Sciences (EXAS), and RadNet (RDNT). These companies are all part of the "medical laboratories" industry.

Aclarion vs.

Invitae (NYSE:NVTA) and Aclarion (NASDAQ:ACON) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends, media sentiment, community ranking and profitability.

61.3% of Invitae shares are owned by institutional investors. Comparatively, 7.5% of Aclarion shares are owned by institutional investors. 0.7% of Invitae shares are owned by insiders. Comparatively, 22.3% of Aclarion shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Invitae received 450 more outperform votes than Aclarion when rated by MarketBeat users. However, 100.00% of users gave Aclarion an outperform vote while only 60.46% of users gave Invitae an outperform vote.

CompanyUnderperformOutperform
InvitaeOutperform Votes
451
60.46%
Underperform Votes
295
39.54%
AclarionOutperform Votes
1
100.00%
Underperform Votes
No Votes

Invitae has a net margin of -299.14% compared to Invitae's net margin of -10,246.33%. Invitae's return on equity of -2,554.98% beat Aclarion's return on equity.

Company Net Margins Return on Equity Return on Assets
Invitae-299.14% -6,100.71% -19.68%
Aclarion -10,246.33%-2,554.98%-251.78%

Invitae has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500. Comparatively, Aclarion has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500.

In the previous week, Aclarion had 1 more articles in the media than Invitae. MarketBeat recorded 2 mentions for Aclarion and 1 mentions for Invitae. Invitae's average media sentiment score of 1.44 beat Aclarion's score of 0.00 indicating that Aclarion is being referred to more favorably in the news media.

Company Overall Sentiment
Invitae Neutral
Aclarion Positive

Invitae presently has a consensus target price of $1.00, suggesting a potential upside of 99,900.00%. Given Aclarion's higher probable upside, equities analysts clearly believe Invitae is more favorable than Aclarion.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Invitae
2 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Aclarion
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Aclarion has lower revenue, but higher earnings than Invitae.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Invitae$481.58M0.00-$3.11B-$5.380.00
Aclarion$80K30.74-$4.91MN/AN/A

Summary

Invitae and Aclarion tied by winning 7 of the 14 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ACON vs. The Competition

MetricAclarionMedical laboratories IndustryMedical SectorNASDAQ Exchange
Market Cap$2.46M$2.24B$5.15B$8.41B
Dividend YieldN/A2.04%2.77%4.04%
P/E RatioN/A20.90149.1217.91
Price / Sales30.74132.002,194.4971.79
Price / CashN/A309.1134.4931.32
Price / Book-0.794.094.854.22
Net Income-$4.91M-$128.24M$110.43M$216.24M
7 Day Performance1.15%-1.53%-0.33%-0.46%
1 Month Performance4.49%-8.43%-1.70%-1.98%
1 Year Performance-98.55%-14.48%-0.84%2.13%

Aclarion Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NVTA
Invitae
1.3831 of 5 stars
$0.02
flat
$1.00
+5,028.2%
-99.9%$5.21M$481.58M0.001,700Gap Down
MDXH
MDxHealth
2.7376 of 5 stars
$2.88
+2.1%
$7.50
+160.4%
-92.6%$4.49M$75.33M0.00300Short Interest ↓
Positive News
FRES
Fresh2 Group
0 of 5 stars
$0.44
-5.9%
N/A-91.0%$3.93M$1.75M0.0075Short Interest ↓
Positive News
Gap Down
OPGN
OpGen
0 of 5 stars
$2.64
-2.2%
N/A-61.1%$3.54M$3.42M-0.0485Short Interest ↑
CNTG
Centogene
0.4327 of 5 stars
$0.36
+0.6%
N/A-52.8%$0.00$52.53M0.00444Short Interest ↑
LH
Laboratory Co. of America
4.8799 of 5 stars
$196.60
-0.9%
$241.86
+23.0%
-14.2%$16.57B$12.16B39.5667,000Positive News
DGX
Quest Diagnostics
4.839 of 5 stars
$142.34
-0.2%
$146.67
+3.0%
+1.3%$15.81B$9.25B19.1648,000Positive News
NTRA
Natera
1.6871 of 5 stars
$111.19
+1.8%
$101.19
-9.0%
+118.4%$13.65B$1.08B-35.643,293Positive News
EXAS
Exact Sciences
4.1714 of 5 stars
$42.93
-3.9%
$93.07
+116.8%
-54.3%$7.92B$2.50B-32.526,600
RDNT
RadNet
3.1485 of 5 stars
$61.25
+0.2%
$57.25
-6.5%
+78.2%$4.53B$1.62B204.1710,288Insider Selling
News Coverage

Related Companies and Tools

This page (NASDAQ:ACON) was last updated on 6/14/2024 by MarketBeat.com Staff

From Our Partners